Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.

American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(34), p. 3543-3543

Journal article published in 2016 by Carlotta Antoniotti, Chiara Cremolini, Fotios Loupakis, Francesca Bergamo, Roberta Grande, Giuseppe Tonini, Silvio Ken Garattini, Gianluca Masi, Francesca Battaglin, Sara Lucchesi, Lisa Salvatore

, Domenico C. Corsi, Francesca Di Fabio, Maria Banzi, Elisa Sensi and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by